🚀 VC round data is live in beta, check it out!
Insight Molecular Valuation Multiples
Discover revenue and EBITDA valuation multiples for Insight Molecular and similar public comparables like ArcticZymes, Alpha Teknova, Pacific Edge, 4basebio and more.
Insight Molecular Overview
About Insight Molecular
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company’s flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx.
Founded
2009
HQ
Employees
49
Website
Sectors
Financials (LTM)
EV
$123M
Insight Molecular Financials
Insight Molecular reported last 12-month revenue of $3M and negative EBITDA of ($19M).
In the same LTM period, Insight Molecular generated $2M in gross profit, ($19M) in EBITDA losses, and had net loss of ($33M).
Revenue (LTM)
Insight Molecular P&L
In the most recent fiscal year, Insight Molecular reported revenue of $2M and EBITDA of ($13M).
Insight Molecular expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $3M | XXX | $2M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | $740K | XXX | XXX | XXX |
| Gross Margin | 64% | XXX | 39% | XXX | XXX | XXX |
| EBITDA | ($19M) | XXX | ($13M) | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (702%) | XXX | XXX | XXX |
| EBIT Margin | (870%) | XXX | (1236%) | XXX | XXX | XXX |
| Net Profit | ($33M) | XXX | ($61M) | XXX | XXX | XXX |
| Net Margin | (1027%) | XXX | (3225%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Insight Molecular Stock Performance
Insight Molecular has current market cap of $138M, and enterprise value of $123M.
Market Cap Evolution
Insight Molecular's stock price is $4.82.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $123M | $138M | 0.0% | XXX | XXX | XXX | $-2.11 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialInsight Molecular Valuation Multiples
Insight Molecular trades at 37.8x EV/Revenue multiple, and (6.5x) EV/EBITDA.
EV / Revenue (LTM)
Insight Molecular Financial Valuation Multiples
As of March 24, 2026, Insight Molecular has market cap of $138M and EV of $123M.
Equity research analysts estimate Insight Molecular's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Insight Molecular has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $138M | XXX | $138M | XXX | XXX | XXX |
| EV (current) | $123M | XXX | $123M | XXX | XXX | XXX |
| EV/Revenue | 37.8x | XXX | 65.2x | XXX | XXX | XXX |
| EV/EBITDA | (6.5x) | XXX | (9.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.4x) | XXX | (5.3x) | XXX | XXX | XXX |
| EV/Gross Profit | 59.6x | XXX | 165.8x | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (2.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Insight Molecular Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Insight Molecular Margins & Growth Rates
Insight Molecular's revenue in the last 12 month grew by 31%.
Insight Molecular's revenue per employee in the last FY averaged $0.1M.
Insight Molecular's rule of 40 is (554%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Insight Molecular's rule of X is (507%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Insight Molecular Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 31% | XXX | 72% | XXX | XXX | XXX |
| EBITDA Margin | (586%) | XXX | (702%) | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | 34% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | (554%) | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | (507%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 182% | XXX | 34% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 332% | XXX | 699% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 404% | XXX | 523% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 1275% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Insight Molecular Public Comps
See public comps and valuation multiples for other Life Sciences Tools comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| ArcticZymes | XXX | XXX | XXX | XXX | XXX | XXX |
| Alpha Teknova | XXX | XXX | XXX | XXX | XXX | XXX |
| Pacific Edge | XXX | XXX | XXX | XXX | XXX | XXX |
| 4basebio | XXX | XXX | XXX | XXX | XXX | XXX |
| SDI Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Insight Molecular M&A Activity
Insight Molecular acquired XXX companies to date.
Last acquisition by Insight Molecular was on XXXXXXXX, XXXXX. Insight Molecular acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Insight Molecular
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialInsight Molecular Investment Activity
Insight Molecular invested in XXX companies to date.
Insight Molecular made its latest investment on XXXXXXXX, XXXXX. Insight Molecular invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Insight Molecular
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Insight Molecular
| When was Insight Molecular founded? | Insight Molecular was founded in 2009. |
| Where is Insight Molecular headquartered? | Insight Molecular is headquartered in United States. |
| How many employees does Insight Molecular have? | As of today, Insight Molecular has over 49 employees. |
| Who is the CEO of Insight Molecular? | Insight Molecular's CEO is Joshua Riggs. |
| Is Insight Molecular publicly listed? | Yes, Insight Molecular is a public company listed on Nasdaq. |
| What is the stock symbol of Insight Molecular? | Insight Molecular trades under IMDX ticker. |
| When did Insight Molecular go public? | Insight Molecular went public in 2015. |
| Who are competitors of Insight Molecular? | Insight Molecular main competitors are ArcticZymes, Alpha Teknova, Pacific Edge, 4basebio. |
| What is the current market cap of Insight Molecular? | Insight Molecular's current market cap is $138M. |
| What is the current revenue of Insight Molecular? | Insight Molecular's last 12 months revenue is $3M. |
| What is the current revenue growth of Insight Molecular? | Insight Molecular revenue growth (NTM/LTM) is 31%. |
| What is the current EV/Revenue multiple of Insight Molecular? | Current revenue multiple of Insight Molecular is 37.8x. |
| Is Insight Molecular profitable? | No, Insight Molecular is not profitable. |
| What is the current EBITDA of Insight Molecular? | Insight Molecular has negative EBITDA and is not profitable. |
| What is Insight Molecular's EBITDA margin? | Insight Molecular's last 12 months EBITDA margin is (586%). |
| What is the current EV/EBITDA multiple of Insight Molecular? | Current EBITDA multiple of Insight Molecular is (6.5x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.